[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100257691":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":27,"locations":38,"responsibleParty":55,"collaborators":18,"id":58,"slug":18,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":18,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":18,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":41,"whyStopped":18,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Fudan University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"radiotherapy group","EXPERIMENTAL","complete resection and adjuvant radiotherapy",[13],"Radiation: adjuvant radiotherapy",{"label":15,"type":16,"description":17,"interventionNames":18},"observation group","NO_INTERVENTION","complete resection",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"RADIATION","adjuvant radiotherapy","50Gy\u002F25Fx",[9],[26],"RT",[28,34],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"Kailiang Wu, MD.PhD.","CONTACT","+86 64175590","86722","wukailiang@aliyun.com",{"name":35,"role":30,"phone":36,"phoneExt":18,"email":37},"Xingwen Fan, MD","+8613651669687","wenxingfan@126.com",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Kailiang Wu","RECRUITING","Shanghai","Shanghai Municipality","20032","China",{"type":47,"coordinates":48},"Point",[49,50],121.45806,31.22222,{"lat":50,"lon":49},[53],{"name":54,"role":30,"phone":31,"phoneExt":32,"email":33},"Kailiang Wu, M.D. Ph. D.",{"type":56,"investigatorFullName":40,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","professor","100257691",false,"NCT02633553","Adjuvant Radiotherapy for Stage II\u002FIII Thymoma After Complete Resection","An Open-label, Multi-center, Randomized Phase III Study of Adjuvant Radiotherapy for Stage II\u002FIII Thymoma After Complete Resection","Inclusion Criteria:\n\n18\\~75 years old; Eastern Cooperative Oncology Group performance status of 0 to 2; Pathologically confirmed masaoka stage II or III thymoma; Have adequate bone marrow, hepatic, and renal function; Patients receive complete resection within 3 months; Written informed consent.\n\nExclusion Criteria:\n\nPatients with distant metastases; Patients underwent radiotherapy or chemotherapy; Patients who have malignancy history excluding carcinoma in situ of cervix in the previous five years; Active clinical pulmonary infection; Pregnant or nursing.","ALL","18 Years","75 Years",{"count":68,"type":69},238,"ESTIMATED","INTERVENTIONAL",[72],"NA","This study is designed to investigate whether adjuvant radiotherapy after complete resection has a better survival for stage II or III thymoma.",[75],"Thymoma",[77,22,17],"thymoma","2026-04-22",{"date":80,"type":81},"2026-04-24","ACTUAL",{"date":83,"type":81},"2018-01-10",{"date":85,"type":69},"2029-12",{"name":5,"class":6},1]